Is the Seeds/Tissue Culture/Bio Technology sector outperforming NIFTY 500?
The 52-week sector comparison is unavailable. 0 of 3 covered companies currently have positive Mansfield relative strength versus NIFTY 500.
20-quarter listed-company comparison
Seeds/Tissue Culture/Bio Technology Stocks in India
Seeds/Tissue Culture/Bio Technology: Rossari Biotech Ltd owns the largest revenue base AND the fastest current growth.
Nifty Seeds/Tissue Culture/Bio Technology Index — Constituents & Performance
The Seeds/Tissue Culture/Bio Technology companies below are the listed Indian Seeds/Tissue Culture/Bio Technology universe this page tracks — the same constituent set people search for as the Nifty Seeds/Tissue Culture/Bio Technology index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
The sector itself · before any single company
How has Seeds/Tissue Culture/Bio Technology moved against NIFTY 500?
The line below covers 5.1 years. Over the most recent two of them this sector is 38% behind NIFTY 500. Earnings across its companies grew 5% on average over the last four reported quarters — close to flat.
ASLEEP · 1y −21.6%✓Price down, no fundamental support1 of 3 companies ahead of NIFTY 500 by 5% or more over three months
RS — · 1/3 >200d (+0) · 1/3 lead (−2) · EPS 2/3↑
Seeds/Tissue Culture/Bio Technology, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Strength anatomy
MixedHow much of the sector is participating, how recently, and whether the movers score well.
Together1 of 3 stocks moving
Fresh0 crossed in the last 4 weeks
Backed by scoresmovers score +16 vs the sector average
Down the cap ladder — bar is now, tick is four weeks ago
Large
1/10
Mid
0/1−1
Small
0/1−1
Participation is not spreading downward this month; the larger companies are still carrying most of it.
Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 3 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
Sector relative strength · before individual stocks
Is Seeds/Tissue Culture/Bio Technology outperforming NIFTY 500?
The 52-week comparison of Seeds/Tissue Culture/Bio Technology against NIFTY 500 is not available from the current market series. 0 of 3 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is broad. Advanced Enzyme Technologies Ltd is the strongest against the sector itself at +11%.
—Sector vs NIFTY 500 · 13 weeks
—Sector vs NIFTY 500 · 52 weeks
0/3Stocks leading NIFTY 500
2/3Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: current leadership is concentrated, so durability matters more than rank.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
The 52-week sector comparison is unavailable. 0 of 3 covered companies currently have positive Mansfield relative strength versus NIFTY 500. Rossari Biotech Ltd leads with revenue of ₹2,550 crore, based on 3 of 3 comparable companies through Jun 2026. Rossari Biotech Ltd has the fastest current revenue growth at 19.4%, across 3 of 3 comparable companies.
Which Seeds/Tissue Culture/Bio Technology company is largest by revenue?
Rossari Biotech Ltd leads with revenue of ₹2,550 crore, based on 3 of 3 comparable companies through Jun 2026.
Which Seeds/Tissue Culture/Bio Technology company is growing fastest?
Rossari Biotech Ltd has the fastest current revenue growth at 19.4%, across 3 of 3 comparable companies.
Which Seeds/Tissue Culture/Bio Technology company has the strongest 4-Factor Sector Score?
Advanced Enzyme Technologies Ltd ranks first at 71.2/100 with 76% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Seeds/Tissue Culture/Bio Technology company has the least gross debt?
Advanced Enzyme Technologies Ltd has the lowest comparable gross debt at ₹32 crore. Rossari Biotech Ltd has the highest at ₹436 crore.
Which Seeds/Tissue Culture/Bio Technology company has the lowest comparable PEG?
Rossari Biotech Ltd has the lowest comparable Guarded PEG at 1.7, among 1 of 3 companies that pass the metric’s comparability rules.
How much history does this Seeds/Tissue Culture/Bio Technology comparison include?
The page compares up to 20 reported quarters per company for fundamentals, CAPEX, debt and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Companies
3
complete canonical membership
Combined market value
₹7.2K Cr
Advanced Enzyme Technologies Ltd
Revenue growing
2/3
positive TTM year-on-year growth
Beating NIFTY 500
0/3
positive Mansfield relative strength
Global company selection
00 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Advanced Enzyme Technologies Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 76% evidence confidence.
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is guarded: positive earnings, positive 5–60% three-year EPS growth, and a positive P/E are required.
1. Advanced Enzyme Technologies Ltd · ADVENZYMES
71.2/100 · Favorable setup · 76% evidence
Exact sum: 27.8 + 17.5 + 12.1 + 13.8 = 71.2
Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
27.8/35Growth & earnings
Revenue 17.1% · PAT 29.1% · OPM change 4 pp
83% evidence
17.5/25Capital efficiency
ROCE 14% · debt/equity 0.02×
80% evidence
12.1/20Valuation
P/E 22.9× · PEG —
35% evidence
13.8/20Relative strength
RS sector 11% · RS bench -0.1% · 1Y -1.2%
100% evidence
2. Rossari Biotech Ltd · ROSSARI
60.4/100 · Mixed-positive evidence · 97% evidence
Exact sum: 20.4 + 12.8 + 12.7 + 14.5 = 60.4
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20.4/35Growth & earnings
Revenue 19.4% · PAT 11.8% · OPM change 0 pp
100% evidence
12.8/25Capital efficiency
ROCE 13.3% · debt/equity 0.33×
100% evidence
12.7/20Valuation
P/E 18× · PEG 1.7
85% evidence
14.5/20Relative strength
RS sector 4.8% · RS bench -6.5% · 1Y -28.5%
100% evidence
3. Bombay Super Hybrid Seeds Ltd · BSHSL
33.6/100 · Adverse evidence · 74% evidence
Exact sum: 5.7 + 12.7 + 12.2 + 3 = 33.6
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5.7/35Growth & earnings
Revenue -4.1% · PAT 0.9% · OPM change -3.5 pp
83% evidence
12.7/25Capital efficiency
ROCE 16% · debt/equity 0.82×
95% evidence
12.2/20Valuation
P/E 34.2× · PEG —
35% evidence
3.0/20Relative strength
RS sector -17.4% · RS bench -16.9% · 1Y -35.5%
70% evidence
01 · compare level, then change
Revenue Scale & Growth Durability
Rossari Biotech Ltd has the highest Revenue among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at ₹2,550 crore. Advanced Enzyme Technologies Ltd is next at ₹746 crore. The same company also holds the highest Revenue growth, at 19.4%. 3 of 3 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Rossari Biotech Ltd is the scale leader at ₹2,550 crore, 241.8% ahead of Advanced Enzyme Technologies Ltd. Rossari Biotech Ltd's growth is 19.4% from a ₹2,550 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderRossari Biotech Ltd · ₹2,550 crore
Gap241.8% versus #2 · Advanced Enzyme Technologies Ltd
Persistence8/8 recent comparable periods
Coverage3/3 companies · 48 observations
Investor read: Rossari Biotech Ltd is the scale benchmark; Rossari Biotech Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Rossari Biotech Ltd's growth falls below Rossari Biotech Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Rossari Biotech Ltd ROSSARI₹2.6K Cr
2Advanced Enzyme Technologies Ltd ADVENZYMES₹746 Cr
3Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified₹344 Cr
Revenue growthfastest growers
1Rossari Biotech Ltd ROSSARI19%
2Advanced Enzyme Technologies Ltd ADVENZYMES17%
3Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified-4.1%
Revenue · company comparison
3/3 level · 3/3 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Rossari Biotech Ltd ROSSARI | ₹697 Cr | 28% | Jun 2026 |
| Advanced Enzyme Technologies Ltd ADVENZYMES | ₹203 Cr | 22% | Mar 2026 |
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | ₹66 Cr | 45% | Mar 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
—
—
—
—
—
₹142 Cr
₹139 Cr
₹147 Cr
₹158 Cr
₹161 Cr
₹158 Cr
₹155 Cr
₹146 Cr
₹169 Cr
₹167 Cr
₹186 Cr
₹185 Cr
₹172 Cr
₹203 Cr
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
—
—
—
—
—
₹69 Cr
₹36 Cr
₹117 Cr
₹34 Cr
₹76 Cr
₹30 Cr
₹157 Cr
₹28 Cr
₹128 Cr
₹46 Cr
₹153 Cr
₹27 Cr
₹98 Cr
₹66 Cr
—
Rossari Biotech Ltd · ROSSARI
₹385 Cr
₹428 Cr
₹439 Cr
₹435 Cr
₹425 Cr
₹389 Cr
₹406 Cr
₹411 Cr
₹483 Cr
₹464 Cr
₹473 Cr
₹490 Cr
₹498 Cr
₹513 Cr
₹580 Cr
₹544 Cr
₹586 Cr
₹582 Cr
₹685 Cr
₹697 Cr
Revenue growth · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
—
—
—
—
—
—
—
—
—
13%
14%
5.4%
-7.6%
5.0%
5.7%
20%
27%
1.8%
22%
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
—
—
—
—
—
—
—
—
—
11%
-16%
34%
-16%
67%
52%
-2.4%
-4.8%
-23%
45%
—
Rossari Biotech Ltd · ROSSARI
—
—
—
—
10%
-9.1%
-7.5%
-5.5%
14%
19%
17%
19%
3.1%
11%
23%
11%
18%
13%
18%
28%
02 · compare level, then change
Operating Economics & Margin Trend
Advanced Enzyme Technologies Ltd has the highest OPM among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at 31%. Rossari Biotech Ltd is next at 12%. The same company also holds the highest Margin change, at +4 percentage points. 3 of 3 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Advanced Enzyme Technologies Ltd leads both opm at 31% and margin change at +4 percentage points.
LeaderAdvanced Enzyme Technologies Ltd · 31%
Gap158.3% versus #2 · Rossari Biotech Ltd
Persistence3/8 recent comparable periods
Coverage3/3 companies · 58 observations
Investor read: Advanced Enzyme Technologies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Advanced Enzyme Technologies Ltd ADVENZYMES31%
2Rossari Biotech Ltd ROSSARI12%
3Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified9.8%
Margin changefastest expanders
1Advanced Enzyme Technologies Ltd ADVENZYMES+4.0 pp
2Rossari Biotech Ltd ROSSARI0.0 pp
3Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified−3.5 pp
Operating margin · company comparison
3/3 level · 3/3 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Advanced Enzyme Technologies Ltd ADVENZYMES | 31% | +4.0 pp | Mar 2026 |
| Rossari Biotech Ltd ROSSARI | 12% | 0.0 pp | Jun 2026 |
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | 9.8% | −3.5 pp | Mar 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
39%
37%
31%
26%
29%
29%
32%
30%
32%
33%
35%
33%
29%
33%
27%
30%
33%
29%
31%
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
6.3%
5.3%
8.8%
8.7%
6.5%
12%
9.3%
11%
8.7%
12%
12%
8.7%
11%
7.8%
13%
10%
15%
9.8%
9.8%
—
Rossari Biotech Ltd · ROSSARI
12%
11%
12%
13%
13%
14%
13%
14%
13%
14%
13%
13%
13%
13%
12%
12%
12%
12%
11%
12%
Margin change · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
−9.8 pp
−11.5 pp
−10.7 pp
−20.3 pp
−10.2 pp
−7.7 pp
+1.4 pp
+4.5 pp
+3.4 pp
+4.0 pp
+3.0 pp
+3.0 pp
−3.0 pp
0.0 pp
−8.0 pp
−3.0 pp
+4.0 pp
−4.0 pp
+4.0 pp
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
+2.1 pp
+0.5 pp
−1.5 pp
+0.7 pp
+0.2 pp
+6.2 pp
+0.6 pp
+2.3 pp
+2.1 pp
+0.5 pp
+2.3 pp
−2.3 pp
+2.3 pp
−4.3 pp
+1.7 pp
+1.4 pp
+4.5 pp
+2.0 pp
−3.5 pp
—
Rossari Biotech Ltd · ROSSARI
−5.7 pp
−5.1 pp
−4.6 pp
−2.8 pp
+1.5 pp
+2.9 pp
+1.1 pp
+0.7 pp
−0.3 pp
0.0 pp
0.0 pp
−1.0 pp
0.0 pp
−1.0 pp
−1.0 pp
−1.0 pp
−1.0 pp
−1.0 pp
−1.0 pp
0.0 pp
03 · compare level, then change
Profit Scale & Acceleration
Advanced Enzyme Technologies Ltd has the highest Net profit among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at ₹173 crore. Rossari Biotech Ltd is next at ₹151 crore. The same company also holds the highest Profit growth, at 29.1%. 3 of 3 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Advanced Enzyme Technologies Ltd leads with ₹173 crore of TTM profit, 14.6% above Rossari Biotech Ltd. Advanced Enzyme Technologies Ltd shows 29.1% growth from a ₹173 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderAdvanced Enzyme Technologies Ltd · ₹173 crore
Gap14.6% versus #2 · Rossari Biotech Ltd
Persistence5/8 recent comparable periods
Coverage3/3 companies · 48 observations
Investor read: Advanced Enzyme Technologies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Advanced Enzyme Technologies Ltd ADVENZYMES₹173 Cr
2Rossari Biotech Ltd ROSSARI₹151 Cr
3Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified₹27 Cr
Profit growthfastest growers
1Advanced Enzyme Technologies Ltd ADVENZYMES29%
2Rossari Biotech Ltd ROSSARI12%
3Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified1.0%
Net profit · company comparison
3/3 level · 3/3 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Advanced Enzyme Technologies Ltd ADVENZYMES | ₹45 Cr | 67% | Mar 2026 |
| Rossari Biotech Ltd ROSSARI | ₹35 Cr | 2.9% | Jun 2026 |
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | ₹4 Cr | 4.5% | Mar 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
—
—
—
—
—
₹28 Cr
₹32 Cr
₹29 Cr
₹35 Cr
₹42 Cr
₹30 Cr
₹35 Cr
₹33 Cr
₹39 Cr
₹27 Cr
₹40 Cr
₹45 Cr
₹43 Cr
₹45 Cr
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
—
—
—
—
—
₹7 Cr
₹2 Cr
₹11 Cr
₹2 Cr
₹7 Cr
₹3 Cr
₹11 Cr
₹2 Cr
₹9 Cr
₹4 Cr
₹12 Cr
₹2 Cr
₹8 Cr
₹4 Cr
—
Rossari Biotech Ltd · ROSSARI
₹26 Cr
₹23 Cr
₹24 Cr
₹29 Cr
₹24 Cr
₹26 Cr
₹29 Cr
₹29 Cr
₹33 Cr
₹34 Cr
₹34 Cr
₹35 Cr
₹35 Cr
₹32 Cr
₹34 Cr
₹34 Cr
₹37 Cr
₹33 Cr
₹46 Cr
₹35 Cr
Profit growth · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
—
—
—
—
—
—
—
—
—
50%
-6.3%
21%
-5.7%
-7.1%
-10%
14%
36%
10%
67%
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
—
—
—
—
—
—
—
—
—
3.5%
64%
4.5%
32%
31%
35%
10%
8.2%
-14%
4.5%
—
Rossari Biotech Ltd · ROSSARI
—
—
—
—
-7.7%
13%
21%
0.0%
38%
31%
17%
21%
6.1%
-5.9%
0.0%
-2.9%
5.7%
3.1%
35%
2.9%
04 · not available
Capacity Spending & Returns On It
No company in this Seeds/Tissue Culture/Bio Technology comparison reports capital expenditure on a comparable basis, so there is nothing to rank here — 0 of 3 companies have a usable current reading. The section is shown rather than removed so an unavailable metric is not mistaken for one that was quietly left out. Filings were read through Jun 2026.
CAPEX is cash spent on property, plant, equipment and other reported capital assets. CAPEX intensity divides that spend by revenue; high intensity is a reinvestment signal, not proof that the reinvestment will earn attractive returns.
Withheld from this comparison: Advanced Enzyme Technologies Ltd (ADVENZYMES) — its two data sources disagree by up to 4% on reported income across 14 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
05 · compare level, then change
Debt Load & Balance-Sheet Headroom
Advanced Enzyme Technologies Ltd has the lowest Gross debt among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at ₹32 crore. Bombay Super Hybrid Seeds Ltd is next at ₹108 crore. Bombay Super Hybrid Seeds Ltd has the lowest Net debt at ₹107 crore, so level and change sit with different companies.
What the numbers say: Bombay Super Hybrid Seeds Ltd has the clearest covered balance-sheet capacity with ₹107 crore and gross debt of ₹108 crore. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.
LeaderAdvanced Enzyme Technologies Ltd · ₹32 crore
Gap70.4% versus #2 · Bombay Super Hybrid Seeds Ltd
PersistenceNot enough history
Coverage3/3 companies · 45 observations
Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.
This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.
Gross debt shows contractual borrowings. Net debt subtracts reported cash; a negative value means net cash. Lower debt can create capacity, but should be read against the scale and capital intensity of the business.
Gross debtlowest gross debt
1Advanced Enzyme Technologies Ltd ADVENZYMES₹32 Cr
2Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified₹108 Cr
3Rossari Biotech Ltd ROSSARI₹436 Cr
Net debtlowest net debt
1Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified₹107 Cr
2Rossari Biotech Ltd ROSSARI₹321 Cr
Debt and balance-sheet capacity · company comparison
3/3 level · 2/3 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Gross debt | Net debt | Reported |
|---|---|---|---|
| Rossari Biotech Ltd ROSSARI | ₹436 Cr | ₹321 Cr | Jun 2026 |
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | ₹108 Cr | ₹107 Cr | Mar 2026 |
| Advanced Enzyme Technologies Ltd ADVENZYMES | ₹32 Cr | — | Mar 2026 |
Full 20-quarter history · every available company
Gross debt · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
—
—
₹35 Cr
—
—
—
₹34 Cr
—
—
—
₹47 Cr
—
—
—
₹39 Cr
—
₹35 Cr
—
₹32 Cr
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
₹2 Cr
₹2 Cr
₹39 Cr
₹39 Cr
₹0 Cr
₹0 Cr
₹53 Cr
₹53 Cr
₹22 Cr
₹22 Cr
₹48 Cr
₹48 Cr
₹37 Cr
₹37 Cr
₹92 Cr
₹92 Cr
₹30 Cr
₹30 Cr
₹108 Cr
—
Rossari Biotech Ltd · ROSSARI
₹4 Cr
₹4 Cr
₹8 Cr
₹8 Cr
₹71 Cr
₹71 Cr
₹74 Cr
₹74 Cr
₹132 Cr
₹132 Cr
₹119 Cr
₹119 Cr
₹161 Cr
₹161 Cr
₹218 Cr
₹218 Cr
₹353 Cr
₹353 Cr
₹436 Cr
₹436 Cr
Net debt · reported quarter history
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
₹1 Cr
₹1 Cr
₹39 Cr
₹39 Cr
₹0 Cr
₹0 Cr
₹53 Cr
₹53 Cr
₹22 Cr
₹22 Cr
₹48 Cr
₹48 Cr
₹37 Cr
₹37 Cr
₹91 Cr
₹91 Cr
₹28 Cr
₹28 Cr
₹107 Cr
—
Rossari Biotech Ltd · ROSSARI
₹-38 Cr
₹-38 Cr
₹-56 Cr
₹-56 Cr
₹-3 Cr
₹-3 Cr
₹-76 Cr
₹-77 Cr
₹53 Cr
₹53 Cr
₹48 Cr
₹51 Cr
₹81 Cr
₹81 Cr
₹112 Cr
₹101 Cr
₹276 Cr
₹276 Cr
₹321 Cr
₹321 Cr
06 · compare level, then change
Return On Capital Employed
Bombay Super Hybrid Seeds Ltd has the highest ROCE among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at 16%. Advanced Enzyme Technologies Ltd is next at 14%. Advanced Enzyme Technologies Ltd has the highest ROCE change at +1 percentage points, so level and change sit with different companies. Its ROCE series carries 15 reported observations across the 20-quarter window.
What the numbers say: Bombay Super Hybrid Seeds Ltd leads ROCE at 16%, 2 percentage points above Advanced Enzyme Technologies Ltd. Advanced Enzyme Technologies Ltd has the strongest latest improvement at +1 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderBombay Super Hybrid Seeds Ltd · 16%
Gap14.3% versus #2 · Advanced Enzyme Technologies Ltd
Persistence0/8 recent comparable periods
Coverage3/3 companies · 31 observations
Investor read: Bombay Super Hybrid Seeds Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified16%
2Advanced Enzyme Technologies Ltd ADVENZYMES14%
3Rossari Biotech Ltd ROSSARI13%
ROCE changefastest improvers
1Advanced Enzyme Technologies Ltd ADVENZYMES+1.0 pp
2Rossari Biotech Ltd ROSSARI+0.3 pp
3Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified−5.0 pp
Return on capital · company comparison
3/3 level · 3/3 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
Withheld from this chart: Advanced Enzyme Technologies Ltd (ADVENZYMES) — its two data sources disagree by up to 4% on reported income across 14 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | 25% | −5.0 pp | Mar 2026 |
| Rossari Biotech Ltd ROSSARI | 17% | +0.3 pp | Jun 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
29%
—
31%
—
31%
—
36%
—
36%
46%
35%
43%
31%
39%
30%
39%
28%
32%
25%
—
Rossari Biotech Ltd · ROSSARI
13%
—
13%
—
15%
—
15%
—
15%
18%
16%
19%
15%
17%
14%
16%
13%
16%
13%
17%
ROCE change · reported quarter history
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
—
—
—
—
+1.3 pp
—
+5.3 pp
—
+5.7 pp
—
−1.2 pp
—
−5.9 pp
−6.9 pp
−4.2 pp
−3.7 pp
−2.2 pp
−6.4 pp
−5.0 pp
—
Rossari Biotech Ltd · ROSSARI
—
—
—
—
+2.1 pp
—
+1.5 pp
—
−0.1 pp
—
+1.0 pp
—
+0.1 pp
−1.3 pp
−2.1 pp
−2.3 pp
−2.0 pp
−1.3 pp
−1.1 pp
+0.3 pp
07 · compare level, then change
Valuation Against Growth & Quality
Rossari Biotech Ltd has the lowest Guarded PEG among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at 1.7×. The same company also holds the lowest P/E, at 18×. 1 of 3 companies report a comparable reading, the latest through Jun 2026. Its Guarded PEG series carries 13 reported observations across the 20-quarter window.
What the numbers say: Rossari Biotech Ltd has the lowest comparable Guarded PEG at 1.7×. Only 1 of 3 companies pass the guard, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderRossari Biotech Ltd · 1.7×
GapNot enough peers
Persistence0/8 recent comparable periods
Coverage1/3 companies · 13 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data sources reconciled. A missing PEG is more honest than a low-base fiction.
Guarded PEGlowest PEG
1Rossari Biotech Ltd ROSSARI1.7
P/Elowest P/E
1Rossari Biotech Ltd ROSSARI18.0
2Advanced Enzyme Technologies Ltd ADVENZYMES22.9
3Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified34.2
Valuation · company comparison
1/3 level · 3/3 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Guarded PEG | P/E | Reported |
|---|---|---|---|
| Rossari Biotech Ltd ROSSARI | 1.7 | 19.9 | Jun 2026 |
| Advanced Enzyme Technologies Ltd ADVENZYMES | — | 20.7 | Mar 2026 |
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | — | 26.7 | Mar 2026 |
Full 20-quarter history · every available company
Guarded PEG · reported quarter history
Rossari Biotech Ltd · ROSSARI
4.9
2.5
2.1
3.2
5.7
—
6.4
4.8
7.3
2.2
1.7
1.6
1.4
1.7
—
—
—
—
—
—
P/E · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
28.4
25.6
25.9
25.1
30.3
32.7
26.5
28.8
30.0
32.9
27.8
29.9
38.0
26.7
21.9
28.1
26.1
22.5
20.7
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
31.2
34.1
38.3
40.1
99.0
194.4
237.2
173.7
128.9
135.2
111.2
90.5
82.9
65.9
50.1
57.0
50.0
41.9
26.7
—
Rossari Biotech Ltd · ROSSARI
86.9
72.5
52.6
48.5
52.5
40.3
32.1
44.8
41.7
37.8
29.8
35.6
37.1
31.7
24.6
27.7
25.8
23.3
16.0
19.9
08 · compare level, then change
Enterprise Value & Book Value
Rossari Biotech Ltd has the lowest EV/EBITDA among the 3 Seeds/Tissue Culture/Bio Technology companies compared here, at 10.1×. Advanced Enzyme Technologies Ltd is next at 11.8×. The same company also holds the lowest P/BV, at 2.03×. 3 of 3 companies report a comparable reading, the latest through Jun 2026. Its EV/EBITDA series carries 20 reported observations across the 20-quarter window.
What the numbers say: Rossari Biotech Ltd leads both ev/ebitda at 10.1× and p/bv at 2.03×.
LeaderRossari Biotech Ltd · 10.1×
Gap14.4% versus #2 · Advanced Enzyme Technologies Ltd
Persistence0/8 recent comparable periods
Coverage3/3 companies · 58 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.
EV/EBITDA includes debt in enterprise value and is useful across different capital structures. P/BV prices the company against its own book. Both are market multiples on reported figures, not intrinsic-value estimates and not forecasts.
EV/EBITDAlowest EV/EBITDA
1Rossari Biotech Ltd ROSSARI10.1
2Advanced Enzyme Technologies Ltd ADVENZYMES11.8
3Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified20.1
P/BVlowest P/BV
1Rossari Biotech Ltd ROSSARI2.0
2Advanced Enzyme Technologies Ltd ADVENZYMES2.2
3Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified7.0
Enterprise and book valuation · company comparison
3/3 level · 3/3 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | EV/EBITDA | P/BV | Reported |
|---|---|---|---|
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | 20.1 | 5.9 | Mar 2026 |
| Advanced Enzyme Technologies Ltd ADVENZYMES | 11.8 | 2.0 | Mar 2026 |
| Rossari Biotech Ltd ROSSARI | 10.1 | 2.5 | Jun 2026 |
Full 20-quarter history · every available company
EV/EBITDA · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
16.5
14.4
13.9
13.6
16.2
17.6
13.8
15.9
17.5
19.2
16.4
17.3
22.3
15.8
12.9
15.9
15.0
12.9
11.8
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
24.6
24.4
28.5
31.3
73.2
145.7
185.5
133.0
100.3
102.2
81.5
70.1
63.2
49.5
39.6
43.8
39.6
32.0
20.1
—
Rossari Biotech Ltd · ROSSARI
54.5
43.7
28.4
23.8
24.8
17.9
14.3
20.7
19.3
18.9
15.3
17.9
19.6
17.2
13.2
14.6
13.3
12.4
8.8
10.1
P/BV · reported quarter history
Advanced Enzyme Technologies Ltd · ADVENZYMES
4.4
3.6
3.2
3.1
2.6
2.7
2.4
2.9
2.9
3.4
3.1
3.5
4.2
2.9
2.3
2.8
2.5
2.2
2.0
—
Bombay Super Hybrid Seeds Ltd · BSHSL⚠ unverified
10.5
9.5
11.9
14.5
25.0
50.0
97.8
73.9
65.5
41.0
34.1
35.7
24.0
16.7
13.9
19.2
13.2
9.7
5.9
—
Rossari Biotech Ltd · ROSSARI
18.7
9.3
6.8
5.8
6.2
4.7
4.1
5.2
4.9
4.5
3.8
5.1
4.8
3.9
3.0
3.2
2.9
2.5
1.8
2.5
09 · let price answer last
Market action
Advanced Enzyme Technologies Ltd has the strongest one-year price move in Seeds/Tissue Culture/Bio Technology at -1.2%. It also leads on Mansfield relative strength against NIFTY at -0.1%. 0 of 3 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-17.
Every price line is indexed to 100 over the chosen window. Mansfield relative strength compares a price ratio with its own 52-week average; zero separates leadership from lagging.
Price and relative strength
Price is rebased to 100 inside the selected window. Pair ratio rebases each selected company against one chosen denominator.
Before the conclusion · check the blind spots
What can make this comparison misleading?
This Seeds/Tissue Culture/Bio Technology comparison names 7 specific ways its own evidence can mislead, all listed below. All 3 companies here report on comparable dates, so no rank carries a stale marker. 1 draws at least one figure from a second feed with too little overlap to cross-check. 1 has second-feed figures withheld because the two sources disagree.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company draws at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; it is marked unverified wherever that figure appears.
- 1 company is missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
- Thin comparisons: Capital expenditure, Valuation have fewer than three usable current readings.
10 · the complete set
Which companies are included?
All 3 companies in the canonical Seeds/Tissue Culture/Bio Technology membership are listed below, largest market value first — nothing is silently dropped, even where a company reports too little to rank. The charts above default to a selective view; this register is the complete set, with each company's own latest reporting date beside it.
AHEAD means the company is beating the index by 5% or more over three months. LAGGING, FUNDAMENTALS UP means it is 20% or more behind over a year while its trailing twelve-month earnings grew 20% or more. Both rules are fixed and applied the same way in every sector.
| Company | Market value | Price | Priced to | Latest fundamentals | Source standing |
|---|---|---|---|---|---|
| Advanced Enzyme Technologies Ltd ADVENZYMESAHEAD21/26 WEEKS | ₹3.6K Cr | ₹317 | 2026-07-19 | Mar 2026 | Second feed withheld |
| Rossari Biotech Ltd ROSSARI | ₹2.7K Cr | ₹490 | 2026-07-19 | Jun 2026 | Cross-checked |
| Bombay Super Hybrid Seeds Ltd BSHSL⚠ unverified | ₹913 Cr | ₹87.0 | 2026-07-19 | Mar 2026 | Includes unverified figures |
How each company's sources stand: 1 of 3 companies draws at least one figure from a second data feed that could not be cross-checked against the primary source, because the two do not share enough reported history to compare. Those figures are marked unverified wherever they appear. 1 of 3 companies has a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Advanced Enzyme Technologies Ltd (ADVENZYMES) — its two data sources disagree by up to 4% on reported income across 14 comparable periods, so its derived ratios are withheld.
Evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 3 Seeds/Tissue Culture/Bio Technology companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-07-24. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-07-24 · weekly price and relative-strength history
Derived metricsGrowth, changes, CAPEX intensity, net debt, guarded PEG and P/BV÷ROE are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing1 cross-checked · 1 unverified · 1 withheld, of 3 graded companies.
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from. Every company's standing is listed in the register above.
Questions investors ask · short, speakable answers
Seeds/Tissue Culture/Bio Technology company comparison FAQs
These 17 answers restate the Seeds/Tissue Culture/Bio Technology comparison above in question form. Every one is computed from the same 3 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-07-24. Nothing here is estimated, and none of it is a recommendation.
What is the Nifty Seeds/Tissue Culture/Bio Technology index?
The Nifty Seeds/Tissue Culture/Bio Technology index tracks India's listed Seeds/Tissue Culture/Bio Technology companies as a single basket. This page follows the same 3 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Seeds/Tissue Culture/Bio Technology sector rather than to its largest constituent. Figures are as of Jun 2026.
Which are the best Seeds/Tissue Culture/Bio Technology stocks in India?
Ranked by this page's four-factor score, Advanced Enzyme Technologies Ltd places first among 3 listed Seeds/Tissue Culture/Bio Technology companies, followed by Rossari Biotech Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Seeds/Tissue Culture/Bio Technology stocks are listed in India?
This comparison covers 3 listed Seeds/Tissue Culture/Bio Technology companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Seeds/Tissue Culture/Bio Technology company is the biggest?
Rossari Biotech Ltd is the largest, with trailing-twelve-month revenue of ₹2,550 crore, ahead of Advanced Enzyme Technologies Ltd at ₹746 crore. That covers 3 of 3 companies with comparable reporting through Jun 2026.
Which Seeds/Tissue Culture/Bio Technology company is growing fastest?
Rossari Biotech Ltd has the fastest revenue growth at 19.4% year on year, across 3 of 3 comparable companies. Fast growth off a small base is not the same as proven scale — check whether the rate holds across several quarters on the chart above before treating it as a trend.
Which Seeds/Tissue Culture/Bio Technology company has the best profit margins?
Advanced Enzyme Technologies Ltd has the highest operating margin at 31%, from 3 of 3 comparable companies. Advanced Enzyme Technologies Ltd shows the biggest recent improvement, at +4 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Seeds/Tissue Culture/Bio Technology company makes the most profit?
Advanced Enzyme Technologies Ltd earns the most, at ₹173 crore of trailing-twelve-month net profit, from 3 of 3 comparable companies. Advanced Enzyme Technologies Ltd has the fastest profit growth at 29.1%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Seeds/Tissue Culture/Bio Technology company earns the highest return on capital?
Bombay Super Hybrid Seeds Ltd leads on return on capital employed at 16%, across 3 of 3 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Seeds/Tissue Culture/Bio Technology stock is the cheapest?
On guarded PEG — where a LOWER number is cheaper — Rossari Biotech Ltd screens cheapest at 1.7×. Only 1 of 3 companies pass the comparability guard, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Which Seeds/Tissue Culture/Bio Technology company has the strongest balance sheet?
Advanced Enzyme Technologies Ltd carries the lowest comparable gross debt at ₹32 crore, from 3 of 3 companies. Absolute rupee debt alone does not settle it, because company scale differs — net debt and debt-to-equity in the chart above carry more information, and a very low-debt balance sheet can also mean under-investment.
Which Seeds/Tissue Culture/Bio Technology stock has the strongest price momentum?
Advanced Enzyme Technologies Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Seeds/Tissue Culture/Bio Technology company scores highest for research priority?
Advanced Enzyme Technologies Ltd scores 71.2 out of 100 with 76% evidence confidence, from 27.8 points on growth and earnings, 17.5 on capital efficiency, 12.1 on valuation and 13.8 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Seeds/Tissue Culture/Bio Technology companies does this comparison cover, and over what period?
It compares 3 listed companies over up to 20 reported quarters of fundamentals and 10 fiscal years of capital allocation, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Seeds/Tissue Culture/Bio Technology sector?
The 3 Seeds/Tissue Culture/Bio Technology companies on this page carry ₹7,180 crore of combined market value. Advanced Enzyme Technologies Ltd is the largest at ₹3,554 crore, about 49% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-07-29.
How is the Seeds/Tissue Culture/Bio Technology sector performing?
0 of the 3 covered Seeds/Tissue Culture/Bio Technology companies are beating NIFTY 500 on Mansfield relative strength. A 52-week sector-versus-index comparison is not available from the current market series for this sector, so it is not quoted. Readings are as of 2026-07-29.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.